Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award : Priority Announcement - Geroscience

University of Toronto

$120,000.00

Advancing Biomarker-Driven Approaches to Agitation in Alzheimer's Disease: Exploring the moderating role of APOE genotype on brain cholesterol metabolism and the contribution of pain-related biomarkers to agitation severity in Alzheimer's, aiming to establish an understanding of the pathophysiology of agitation that guide safe and effective interventions.

FY 2025-26

Summary
Alzheimer's disease (AD) affects millions worldwide and places a heavy burden on families and caregivers. Beyond memory impairment, many folks with AD experience psychiatric syndromes that they never had before their diagnosis. Agitation is one of the most distressing symptoms. It can involve restlessness and aggression (both physical and vocal), and causes significant emotional distress. Agitation increases caregiver stress, hospitalization, long-term care admission, and mortality. Current medications can reduce agitation but can cause serious side effects. Safer treatments are needed. This series of projects aims to improve our understanding of the biological causes of agitation in AD by examining specific genetic, metabolic, and pain-related factors. One focus of the APOE gene is that carrying the e4 version increases the risk of AD and may change how the brain processes cholesterol. I will measure a cholesterol by-product in the blood, called 24-hydroxycholesterol (24-OHC), which decreases as AD progresses. Lower 24-OHC levels are associated with worse agitation, but we do not know if the risk gene (APOE e4) influences that relationship. I predict that the relationship will be more pronounced in people with the risk gene compared to those without. Pain is another important trigger for agitation, mainly because people in the more advanced stages of AD cannot communicate their pain clearly. I will investigate two pain-related markers in the blood: contactin-1, a protein associated with pain, and the balance between two brain chemicals, quinolinic acid and kynurenic acid, which regulate how the brain responds to pain. Changes in these markers reflecting higher pain will likely be associated with greater agitation. These projects will collect samples and data from a clinical trial of patients with AD and agitation. By identifying biological markers of agitation, this work could help distinguish patients whose symptoms are driven by pain from those with other causes.
Program
Doctoral Research Award : Priority Announcement - Geroscience
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
560914
Name
Feldman Oriel
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Advancing Biomarker-Driven Approaches to Agitation in Alzheimer's Disease: Exploring the moderating role of APOE genotype on brain cholesterol metabolism and the contribution of pain-related biomarkers to agitation severity in Alzheimer's, aiming to establish an understanding of the pathophysiology of agitation that guide safe and effective interventions.
Programtype2
Summer Student Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award : Priority Announcement - Geroscience
Keyworddelim
Agitation; Alzheimer'S Disease; Biomarkers; Cholesterol Metabolism; Pain; Personalized Care
Abstract
Alzheimer's disease (AD) affects millions worldwide and places a heavy burden on families and caregivers. Beyond memory impairment, many folks with AD experience psychiatric syndromes that they never had before their diagnosis. Agitation is one of the most distressing symptoms. It can involve restlessness and aggression (both physical and vocal), and causes significant emotional distress. Agitation increases caregiver stress, hospitalization, long-term care admission, and mortality. Current medications can reduce agitation but can cause serious side effects. Safer treatments are needed. This series of projects aims to improve our understanding of the biological causes of agitation in AD by examining specific genetic, metabolic, and pain-related factors. One focus of the APOE gene is that carrying the e4 version increases the risk of AD and may change how the brain processes cholesterol. I will measure a cholesterol by-product in the blood, called 24-hydroxycholesterol (24-OHC), which decreases as AD progresses. Lower 24-OHC levels are associated with worse agitation, but we do not know if the risk gene (APOE e4) influences that relationship. I predict that the relationship will be more pronounced in people with the risk gene compared to those without. Pain is another important trigger for agitation, mainly because people in the more advanced stages of AD cannot communicate their pain clearly. I will investigate two pain-related markers in the blood: contactin-1, a protein associated with pain, and the balance between two brain chemicals, quinolinic acid and kynurenic acid, which regulate how the brain responds to pain. Changes in these markers reflecting higher pain will likely be associated with greater agitation. These projects will collect samples and data from a clinical trial of patients with AD and agitation. By identifying biological markers of agitation, this work could help distinguish patients whose symptoms are driven by pain from those with other causes.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Feldman, Oriel
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~